



US 20250257334A1

(19) **United States**(12) **Patent Application Publication**
LEE et al.(10) **Pub. No.: US 2025/0257334 A1**(43) **Pub. Date: Aug. 14, 2025**(54) **NOVEL VARIANT OF PTS TRANSPORTER
SUBUNIT EIIC AND 5'-INOSINIC ACID
PRODUCTION METHOD USING SAME**(71) Applicant: **DAESANG CORPORATION**, Seoul
(KR)(72) Inventors: **Sun Hee LEE**, Seoul (KR); **Tae Yeol
CHOI**, Seoul (KR); **Hyun Ho KIM**,
Seoul (KR); **Dong Hyun KIM**, Seoul
(KR); **Hyun Sook KIM**, Seoul (KR);
Jong Hwan SHIN, Seoul (KR)(73) Assignee: **DAESANG CORPORATION**, Seoul
(KR)(21) Appl. No.: **18/880,346**(22) PCT Filed: **Aug. 31, 2023**(86) PCT No.: **PCT/KR2023/012972**

§ 371 (c)(1),

(2) Date: **Dec. 31, 2024**(30) **Foreign Application Priority Data**

Apr. 11, 2023 (KR) 10-2023-0047745

Publication Classification(51) **Int. Cl.****C12N 9/12** (2006.01)**C12N 15/77** (2006.01)**C12P 19/32** (2006.01)(52) **U.S. Cl.**CPC **C12N 9/1205** (2013.01); **C12N 15/77**
(2013.01); **C12P 19/32** (2013.01)

(57)

ABSTRACT

The present invention relates to a novel PTS transporter subunit EIIC variant and a method of producing 5'-inosinic acid using the same. The PTS transporter subunit EIIC variant is obtained by substituting one or more amino acids in the amino acid sequence constituting PTS transporter subunit EIIC to change the activity of the protein, and a recombinant microorganism comprising the PTS transporter subunit EIIC variant is capable of efficiently producing 5'-inosinic acid.



Specification includes a Sequence Listing.

Fig. 1



NOVEL VARIANT OF PTS TRANSPORTER SUBUNIT EIIC AND 5'-INOSINIC ACID PRODUCTION METHOD USING SAME

TECHNICAL FIELD

[0001] The present invention relates to a novel PTS transporter subunit EIIC variant and a method of producing 5'-inosinic acid using the same.

BACKGROUND ART

[0002] 5'-inosinic acid (or inosine monophosphate (IMP)) is an intermediate in the metabolic system of nucleic acid biosynthesis, and not only plays an important physiological role in the bodies of plants and animals, but is also used in various applications, including food, medicine, and various medical applications. In particular, 5'-inosinic acid is a nucleic acid-based seasoning, which has drawn much attention as a savory seasoning, because it has significant synergistic effects on taste when used together with monosodium glutamate (MSG)

[0003] Methods for producing 5'-inosinic acid include a method of enzymatically degrading ribonucleic acid extracted from yeast cells, a method of chemically phosphorylating inosine produced by fermentation, etc.

[0004] Recently, a method of culturing a 5'-inosinic acid-microorganism and recovering 5'-inosinic acid producing accumulated in the medium has been mainly used.

[0005] For the production of 5'-inosinic acid using microorganisms, in order to improve the efficiency of production of 5'-inosinic acid, there has been development of a variety of recombinant strains or mutant strains having excellent 5'-inosinic acid productivity by applying genetic recombination technology to microorganisms such as *Escherichia coli* and *Corynebacterium*, which are widely used in the production of useful substances such as nucleic acids or L-amino acids, and methods of producing 5'-inosinic acid using the same. In particular, there have been attempts to increase the production of 5'-inosinic acid by targeting genes such as enzymes, transcription factors and transport proteins, which are involved in the biosynthetic pathway of 5'-inosinic acid, or by inducing mutations in promoters that regulate the expression of these genes. However, there are dozens to hundreds of types of proteins such as enzymes, transcription factors and transport proteins, which involved directly or are indirectly in the production of 5'-inosinic acid, and thus much research is still needed on the increase in 5'-inosinic acid productivity by changes in the activity of these proteins.

[0006] [Prior Art Documents]

[0007] [Patent Documents]

[0008] Korean Patent No. 10-116602

DISCLOSURE

Technical Problem

[0009] An object of present invention is to provide a novel PTS transporter subunit EIIC variant.

[0010] Another object of the present invention is to provide a polynucleotide encoding the variant.

[0011] Still another object of the present invention is to provide a transformant comprising the variant Or polynucleotide.

[0012] Yet another object of the present invention is to
[0013] provide a method of producing 5'-inosinic acid using the transformant.

Technical Solution

[0014] One aspect of the present invention provides a PTS transporter subunit EIIC variant consisting of the amino acid sequence of SEQ ID NO: 2 in which alanine at position 281 in the amino acid sequence of SEQ ID NO: 4 is substituted with valine.

[0015] As used in the present invention, the term "PTS transporter subunit EIIC" is a component of the phosphoenolpyruvate-dependent sugar phosphotransferase system (PTS), a major carbohydrate active transport system, and catalyzes the phosphorylation of incoming sugar substrates concomitantly with their translocation across the cell membrane, and it may be a polypeptide or protein consisting of the amino acid sequence of SEQ ID NO: 4 and having PTS transporter subunit EIIC activity.

[0016] Information on the nucleic acid and protein sequences of the PTS transporter subunit EIIC is available from known sequence databases (e.g., GenBank, UniProt),

[0017] According to one embodiment of the present invention, the PTS transporter subunit EIIC may be encoded by the nucleotide sequence of SEQ ID NO: 3.

[0018] The amino acid sequence of the PTS transporter subunit EIIC according to the present invention or the nucleotide sequence encoding the same may include a nucleotide sequence or amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% homology or identity to the amino acid sequence of SEQ ID NO: 4 or the nucleotide sequence of SEQ ID NO: 3. As used herein, the term "identity" the "homology" or means percentage rate of identity between two sequences, which is determined by aligning the reference nucleotide sequence or amino acid sequence and any other nucleotide sequence or amino acid sequence to correspond to each other as much as possible and analyzing the aligned sequences.

[0019] According to one embodiment of the present invention, the PTS transporter subunit EIIC may be derived from wild-type *Corynebacterium stationis*.

[0020] As used in the present invention, the term "variant" refers to a protein that has an amino acid sequence different from the amino acid sequence before mutation by the conservative substitution and/or modification of one or more amino acids at the N-terminus, C-terminus of and/or within the amino acid sequence, which result(s) from mutation in the nucleotide sequence of the gene encoding the protein, but retains the functions or properties of the protein before mutation. As used herein, the term "conservative substitution" means substituting one amino acid with another amino acid having similar structural and/or chemical properties. The conservative substitution may have little or no impact on the activity of the protein or polypeptide. In addition, the term "modification" refers to substitution, insertion, deletion, or the like of one or more amino acids. The amino acid is selected from among alanine (Ala, A), isoleucine (Ile, I), valine (Val, V), leucine (Leu, L), methionine (Met, M), asparagine (Asn, N), cysteine (Cys, C), glutamine (Gln, Q), serine (Ser, S), threonine (Thr, T), phenylalanine (Phe, F), tryptophan (Trp, W), tyrosine (Tyr, Y), aspartic acid (Asp, D), glutamic acid (Glu, E), arginine (Arg, R), histidine (His, H), lysine (Lys, K), glycine (Gly, G), and proline (Pro, P).

[0021] In addition, some variants include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed, or those in which a portion has been removed from the N-and/or C-terminus of a mature protein.

[0022] The variant may have increased (enhanced), unchanged, or decreased (weakened) ability compared to that of the protein before mutation. Here, the term “increased or enhanced” includes: a case in which the activity of the protein itself has increased compared to the activity of the protein before mutation; a case in which the overall activity of the protein in the cell is higher than that in the wild-type strain or the strain expressing the protein before mutation due to increased expression or translation of the gene encoding the protein; and a combination thereof. In addition, the term “decreased or weakened” includes: a case in which the activity of the protein itself has decreased compared to the activity of the protein before mutation; a case in which the overall activity of the protein in the cell is lower than that in the wild-type strain or the strain expressing the protein before mutation due to reduced expression or translation of the gene encoding the protein; and a combination thereof. In the present invention, the term “variant” may be used interchangeably with terms such as variant type, modification, variant polypeptide, mutated protein, mutation, and the like.

[0023] The PTS transporter subunit EIIC variant according to the present invention may comprise an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% homology or identity to the amino acid sequence of SEQ ID NO: 2.

[0024] Another aspect of the present invention provides a polynucleotide encoding the PTS transporter subunit EIIC variant.

[0025] As used in the present invention, the term “polynucleotide” refers to a DNA or RNA strand having a certain length or more, which is a long-chain polymer of nucleotides formed by linking nucleotide monomers via covalent bonds. More specifically, the term “polynucleotide” refers to a polynucleotide fragment encoding the variant.

[0026] According to one embodiment of the present invention, the polynucleotide may comprise a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 2.

[0027] More specifically, the polynucleotide may comprise the nucleotide sequence of SEQ ID NO: 1 in which nucleotide “c” at position 842 in the nucleotide sequence of SEQ ID NO: 3 encoding PTS transporter subunit EIIC is substituted with nucleotide “t”.

[0028] Still another aspect of the present invention provides a vector comprising a polynucleotide encoding the PTS transporter subunit EIIC variant.

[0029] Yet another aspect of the present invention provides a transformant comprising the PTS transporter subunit EIIC variant or the polynucleotide.

[0030] As used in the present invention, the term “vector” refers to any type of nucleic acid sequence transfer structure that is used as a means for transferring and expressing a gene of interest in a host cell. Unless otherwise specified, the “vector” one term may mean allowing the nucleic acid sequence contained therein to be expressed after insertion into the host cell genome and/or one allowing the nucleic acid sequence to be expressed independently. This vector comprises essential regulatory elements operably linked so

that an inserted gene can be expressed. As used herein, the term “operably linked” means that a gene of interest and regulatory sequences thereof are functionally linked together in a manner enabling gene expression, and the “regulatory elements” include a promoter for initiating transcription, any operator sequence for regulating transcription, a sequence encoding suitable mRNA ribosome-binding sites, and a sequence for regulating termination of transcription and translation.

[0031] The vector in the present invention is not particularly limited as long as it may replicate in a host cell, and any vector known in the art may be used. Examples of the vector include a natural or recombinant plasmid, cosmid, virus and bacteriophage. Examples of a phage vector or cosmid vector include, but are not limited to, pWE15, M13, λ MBL3, λ MBL4, λ IXII, λ SHII, λ APII, λ t10, λ t11, Charon4A, and Charon21A, and examples of a plasmid vector include, but are not limited to, pBR series, pUC series, pBluescriptII series, pGEM series, pTZ series, pCL series, and pET series.

[0032] The vector may typically be constructed as a vector for cloning or as a vector for expression. The vector for expression may be a conventional vector that is used in the art to express a foreign gene or protein in a plant, animal, or microorganism, and may be constructed through various methods known in the art.

[0033] As used in the present invention, the term “recombinant vector” may be transformed into a suitable host cell, and then may replicate regardless of the genome of the host cell or may be integrated into the genome itself. In this case, the “suitable host cell” may contain a replication origin, which is a particular nucleotide sequence which enables the vector to replicate in the suitable host cell and from which replication starts. For example, when the vector used is an expression vector and uses a prokaryotic cell as a host, the vector generally comprises a strong promoter capable of promoting transcription (e. g., pL₄ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.), a ribosome binding site for initiation of translation, and a transcription/translation termination sequence. When a eukaryotic cell is used as a host, the vector comprises a replication origin operating in the eukaryotic cell, and examples of the replication origin include, but are not limited to, an f1 replication origin, an SV40 replication origin, a pMB1 replication origin, an adeno replication origin, an AAV replication origin, and a BBV replication origin. In addition, the recombinant vector may comprise a promoter derived from the genome of a mammalian cell (e.g., metallothionein promoter) or a promoter derived from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, HSV-tk promoter, etc.), and generally has a polyadenylation sequence as a transcription termination sequence.

[0034] The recombinant vector may comprise a selection marker. The selection marker serves to select a transformant (host cell) transformed with the vector, and since only cells expressing the selection marker can survive in the medium treated with the selection marker, it is possible to select transformed cells. Representative examples of the selection marker include, but are not limited to, kanamycin, streptomycin, and chloramphenicol.

[0035] The transformant may be produced by inserting the recombinant vector into a host cell, and the transformant may be obtained by introducing the recombinant vector into an appropriate host cell. The host cell is a cell capable of

stably and continuously cloning or expressing the expression vector, and any host cell known in the art may be used.

[0036] Where the vector is transformed into prokaryotic cells to generate recombinant microorganisms, examples of host cells that may be used include, but are not limited to, *E. coli* sp. strains such as *E. coli* DH5 α , *E. coli* JM109, *E. coli* BL21, *E. coli* RR1, *E. coli* LE392, *E. coli* B, *E. coli* X 1776, *E. coli* W3110, and *E. coli* XL1-Blue, *Bacillus* sp. strains such as subtilis *Bacillus* and *Bacillus thuringiensis*, *Corynebacterium* sp. strains such as *Corynebacterium glutamicum* and *Corynebacterium stationis*, and various Enterobacteriaceae strains such as *Salmonella typhimurium*, *Serratia marcescens*, and *Pseudomonas* species.

[0037] Where the vector is transformed into eukaryotic cells to generate recombinant microorganisms, examples of host cells that may be used include, but are not limited to, yeast (e.g., *Saccharomyces cerevisiae*), insect cells, plant cells and animal cells, such as Sp2/0, CHO K1, CHO DG44;PER.C6, W138, BHK, COS7, 293, HepG2, Huh7, 3T3, RIN, and MDCK cell lines.

[0038] As used in the present invention, the term “transformation” refers to a phenomenon in which external DNA is introduced into a host cell, thereby artificially causing genetic changes, and the term “transformant” refers to a host cell into which external DNA has been introduced and in which the expression of the gene of interest is stably maintained.

[0039] The transformation may be performed using a suitable vector introduction technique selected depending on the host cell, so that the gene of interest or a recombinant vector comprising the same may be expressed in the host cell. For example, introduction of the vector may be performed by electroporation, heat-shock, calcium phosphate (CaPO₄) precipitation, calcium chloride (CaCl₂) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, lithium acetate-DMSO method, or any combination thereof, without being limited thereto. As long as the transformed gene may be expressed in the host cell, it may be inserted into the chromosome of the host cell, or may exist extrachromosomally, without being limited thereto.

[0040] The transformant may include a cell transfected, transformed, or infected with the recombinant vector of the present invention in vivo or in vitro, and may be used in the same sense as a recombinant host cell, a recombinant cell, or a recombinant microorganism.

[0041] Genes inserted into the recombinant vector of the present invention may be introduced into a host cell such as a *Corynebacterium* sp. strain by homologous recombination crossover.

[0042] According to one embodiment of the present invention, the transformant may be a *Corynebacterium* sp. microorganism. The *Corynebacterium* sp. microorganism may be, but is not limited to, *Corynebacterium glutamicum*, *Corynebacterium crudilactis*, *Corynebacterium deserti*, *Corynebacterium callunae*, *Corynebacterium suranareae*, *Corynebacterium lubricantis*, *Corynebacterium doosanense*, *Corynebacterium efficiens*, *Corynebacterium uterequi*, *Corynebacterium stationis*, *Corynebacterium pacaeense*, *Corynebacterium singulare*, *Corynebacterium humireducens*, *Corynebacterium marinum*, *Corynebacterium halotolerans*, *Corynebacterium spheniscorum*, *Corynebacterium freiburgense*, *Corynebacterium striatum*, *Corynebacterium canis*, *Corynebacterium ammoniagenes*,

Corynebacterium renale, *Corynebacterium pollutisoli*, *Corynebacterium imitans*, *Corynebacterium caspium*, *Corynebacterium testudinoris*, *Corynebacterium pseudopelargi*, or *Corynebacterium flavesceus*.

[0043] The transformant in the present invention may be a strain either comprising the above-described PTS transporter subunit EIIC variant or a polynucleotide encoding the same or comprising the vector comprising the same, a strain expressing the PTS transporter subunit EIIC variant or the polynucleotide, or a strain having activity for the PTS transporter subunit EIIC variant, without being limited thereto.

[0044] The transformant of the present invention may comprise other protein variants or genetic mutations, in addition to the PTS transporter subunit EIIC variant.

[0045] According to one embodiment of the present invention, the transformant may have the ability to produce 5'-inosinic acid.

[0046] The 5'-inosinic acid is a nucleic acid-based compound that gives flavor to food, especially umami (savory) taste, and is used with the same meaning as inosine monophosphate (IMP).

[0047] The transformant may naturally have the ability to produce 5'-inosinic acid or may be one artificially endowed with the ability to produce 5'-inosinic acid.

[0048] According to one embodiment of the present invention, the transformant may have an increased ability to produce 5'-inosinic acid, due to a change in PTS transporter subunit EIIC activity.

[0049] As used in the present invention, the term “increased ability to produce” means that 5'-inosinic acid productivity has increased compared to that of the parent strain. As used herein, the term “parent strain” refers to a wild-type strain or mutant strain to be mutated, and includes a strain that is to be mutated directly or to be transformed with a recombinant vector or the like. In the present invention, the parent strain may be a wild-type *Corynebacterium* sp. strain or a *Corynebacterium* sp. strain mutated from the wild-type strain.

[0050] The transformant according to the present invention exhibits an increased ability to produce 5'-inosinic acid compared to the parent strain, due to the change in PTS transporter subunit EIIC activity caused by introduction of the PTS transporter subunit EIIC variant thereinto. More specifically, the amount of 5'-inosinic acid produced by the transformant may be at least 18, 5%, 108, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than that produced by the parent strain, or may be 1.1-fold, 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, or 10-fold higher than that produced by the parent strain, without being limited thereto. For example, the amount of 5'-inosinic acid produced by the transformant comprising the PTS transporter subunit EIIC variant may be at least 5%, specifically 5 to 50% (preferably 10 to 40%) higher than that produced by the parent strain.

[0051] Still yet another aspect of the present invention

[0052] provides a method for producing 5'-inosinic acid, comprising steps of: culturing the transformant in a medium; and recovering 5'-inosinic acid from the transformant or the medium in which the transformant has been cultured.

[0053] The culturing may be performed using a suitable medium and culture conditions known in the art, and any

person skilled in the art may easily adjust and use the medium and the culture conditions. Specifically, the medium may be a liquid medium, without being limited thereto. Examples of the culturing method include, but are not limited to, batch culture, continuous culture, fed-batch culture, or a combination thereof.

[0054] According to one embodiment of the present invention, the medium should meet the requirements of a specific strain in a proper manner, and may be appropriately modified by a person skilled in the art. For culture media for *Escherichia* sp. strains, reference may be made to, but not limited to, a known document (Manual of Methods for General Bacteriology, American Society for Bacteriology, Washington D.C., USA, 1981).

[0055] According to one embodiment of the present invention, the medium may contain various carbon sources, nitrogen sources, and trace element components. Examples of carbon sources that may be used include: sugars and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch, and cellulose; oils and fats such as soybean oil, sunflower oil, castor oil, and coconut oil; fatty acids such as palmitic acid, stearic acid, and linoleic acid; alcohols such as glycerol and ethanol; and organic acids such as acetic acid. These substances may be used individually or as a mixture, without being limited thereto. Examples of nitrogen sources that may be used include peptone, yeast extract, meat extract, malt extract, corn steep liquor, soybean meal, urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate, and ammonium nitrate. The nitrogen sources may also be used individually or as a mixture, without being limited thereto. Examples of phosphorus sources that may be used include, but are not limited to, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts. In addition, the culture medium may contain, but is not limited to, metal salts such as magnesium sulfate or iron sulfate, which are required for growth. In addition, the culture medium may contain essential growth substances such as amino acids and vitamins. Moreover, suitable precursors may be used in the culture medium. The medium or individual components may be added to the culture medium batchwise or in a continuous manner by a suitable method during culturing, without being limited thereto.

[0056] According to one embodiment of the present invention, the pH of the culture medium may be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid to the microorganism culture medium in an appropriate manner during the culturing. In addition, during the culturing, foaming may be suppressed using an anti-foaming agent such as a fatty acid polyglycol ester. Additionally, to keep the culture medium in an aerobic condition, oxygen or an oxygen-containing gas (for example, air) may be injected into the culture medium. The temperature of the culture medium may be generally 20° C. to 45° C., for example, 25° C. to 40° C. The culturing may be continued until a desired amount of a useful substance is produced. For example, the culturing time may be 10 hours to 160 hours.

[0057] According to one embodiment of the present invention, in the step of recovering 5'-inosinic acid from the cultured transformant the medium in which the transformant has been cultured, the produced 5'-inosinic acid may be collected or recovered from the medium using a suitable

method known in the art depending on the culture method. Examples of a method that may be used to recover the produced 5'-inosinic acid include, but are not limited to, centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, fractional dissolution (e.g., ammonium sulfate precipitation), chromatography (e.g., ion exchange, affinity, hydrophobicity and size exclusion), and the like.

[0058] According to one embodiment of the present invention, the step of recovering 5'-inosinic acid may be performed by centrifuging the culture medium at a low speed to remove biomass and separating the obtained supernatant through ion-exchange chromatography.

[0059] According to one embodiment of the present invention, the step of recovering 5'-inosinic acid may include a process of purifying the 5'-inosinic acid.

Advantageous Effects

[0060] The PTS transporter subunit EIIC variant according to the present invention is obtained by substituting one or more amino acids in the amino acid sequence constituting

[0061] PTS transporter subunit EIIC to change the activity of the protein, and a recombinant microorganism comprising the PTS transporter subunit EIIC variant is capable of efficiently producing 5'-inosinic acid.

BRIEF DESCRIPTION OF DRAWINGS

[0062] FIG. 1 shows the structure of a pk19msb plasmid according to one embodiment of the present invention.

MODE FOR INVENTION

[0063] Hereinafter, the present invention will be described in more detail. However, this description is merely presented by way of example to facilitate the understanding of the present invention, and the scope of the present invention is not limited by this exemplary description.

Example 1. Construction of Strain Expressing PTS Transporter Subunit EIIC Variant

[0064] To evaluate the effect of a variant (SEQ ID NO: 2) having a substitution of valine (V) for alanine (A) at position 281 in the amino acid sequence of PTS transporter subunit EIIC (SEQ ID NO: 4) on the production of 5'-inosinic acid, the present inventors constructed a vector for expressing the PTS transporter subunit EIIC variant and a strain into which the vector has been introduced.

1-1. Construction of Vector for Expression of PTS Transporter Subunit EIIC Variant

[0065] Using the genomic DNA of wild-type *Corynebacterium stationis* ATCC6872 as a template, PCR reactions were performed using a primer pair of primers 1 and 2 and a primer pair of primers 3 and 4, respectively. Thereafter, using the two PCR products as templates, overlapping PCR was performed using a primer pair of primers 1 and 4 to obtain a single fragment. The PCR fragment and a pK19msb plasmid (SEQ ID NO: 5) were treated with the restriction enzyme *smal* (NEB) and ligated together using T4 ligase. The resulting plasmid was named pK FP.

[0066] The PCR amplification was performed using Pfu PreMix (Bioneer) under the following conditions: denaturation at 95° C. for 5 min, and then 30 cycles, each consisting

of 95° C. for 30 sec, 58° C. for 30 sec, and 72° C. for 1 min and 30 sec, followed by reaction at 72° C. for 5 min.
[0067] The primer sequences used for plasmid construction are shown in Table 1 below.

TABLE 1

Primer name	SEQ ID NO.	Primer sequence (5'→3')
Primer 1	6	CGGCAAAGCGCACCTGAAGA
Primer 2	7	CCGCAGCAACGACTTCGTTC
Primer 3	8	TGAACGAAGTCGTTGCTGCGG
Primer 4	9	TCCATGAGCCGATCCACATTGCG

1-2. Construction of Mutant Strain into which PTS Transporter Subunit EIIC Variant has been Introduced
[0068] An electrocompetent cell preparation method, modification of the method of van der Rest et al., was used as a method for transformation of *Corynebacterium stationis* KCCM13339P.
[0069] First, *Corynebacterium stationis* KCCM13339P was primarily cultured in 10 mL of 2YT medium (containing 16 g/l of tryptone, 10 g/l of yeast extract, and 5 g/l of sodium chloride) supplemented with 2% glucose, thus preparing a seed culture. Isonicotinic acid hydrazine at a concentration of 1 mg/ml and 2.5% glycine were added to 100 ml of 2YT medium free of glucose. Next, the seed culture was inoculated into the 2YT medium to reach an OD610 value of 0.3, and then cultured at 30° C. and 180 rpm for 5 to 8 hours so that the OD610 value reached 0.6 to 0.7. The culture was kept on ice for 30 minutes, and then centrifuged at 3,500 rpm at 4° C. for 10 minutes. Thereafter, the supernatant was discarded and the precipitated *Corynebacterium stationis* KCCM13339P was washed 4 times with a 10% glycerol solution and finally re-suspended in 0.5 ml of a 10% glycerol solution, thereby preparing Competent cells. Electroporation was performed using a Bio-Rad electroporator. The prepared competent cells and the constructed pK_FP vector were placed in an electroporation cuvette (0.2 mm), and then subjected to electroporation under conditions of 2.5 kV, 200 Q and 12.5 F. Immediately after completion of the electroporation, 1 ml of regeneration (RG) medium (containing 18.5 g/l brain heart infusion and 0.5 M sorbitol) was added to the cells which were then heat-treated at 46° C. for 6 minutes. Next, the cells were cooled at room temperature, transferred into a 15-ml cap tube, incubated at 30° C. for 2 hours, and plated on a selection medium (containing 5 g/l tryptone, 5 g/l NaCl, 2.5 g/l yeast extract, 18.5 g/l brain heart infusion powder, 15 g/l agar, 91 g/l sorbitol, and 20 µg/l kanamycin). The cells were cultured at 30° C. for 72 hours, and the generated colonies were cultured in medium until the stationary phase to induce secondary recombination. Then, the cells were diluted to 10⁻⁵ to 10⁻⁷, and plated on an antibiotic-free plate medium (containing 10% sucrose), and a strain having no kanamycin resistance and grown on the medium containing 10% sucrose was selected and named IFP-1.

Experimental Example 1. Evaluation of 5'-Inosinic Acid Productivity of Strain Expressing PTS Transporter Subunit EIIC Variant

[0070] 5'-Inosinic acid productivity was compared between the parent strain KCCM13339P and the mutant strain IFP-1 into which the PTS transporter subunit EIIC variant has been introduced.

[0071] Each strain (parent strain or mutant strain) was inoculated at 1% by volume into a 100-ml flask containing 10 mL of the medium for 5'-inosinic acid production shown in Table 2 below, and cultured with shaking at 200 rpm at 34° C. for 45 hours. After completion of the culturing, the Concentration of 5'-inosinic acid in medium was the measured using HPLC (Agilent), and the results are shown in Table 3 below.

TABLE 2

Component	Content
Glucose	70 g/L
(NH ₄) ₂ SO ₄	2 g/L
MgSO ₄	1 g/L
Urea	2 g/L
Yeast extract	20 g/L
KH ₂ PO ₄	2 g/L
FeSO ₄	10 mg/L
MnSO ₄	10 mg/L
Thiamine_HCl	5 mg/L
biotin	20 µg/L
Cystein	20 mg/L
Bata-alanine	20 mg/L
Adenine	30 mg/L

TABLE 3

Strain	5'-inosinic acid production (g/L)
KCCM13339P	19.7
IFP-1	23.2

[0072] As shown in Table 3 above, it was confirmed that the amount of 5'-inosinic acid produced by the mutant strain into which the PTS transporter subunit EIIC variant has been introduced was increased by about 18% compared to that produced by the parent due to substitution of alanine at position 281 with valine. These results suggest that introduction of a point mutation into PTS transporter subunit EIIC provides a significant effect on 5'-inosinic acid productivity.

[0073] So far, the present invention has been described with reference to the preferred embodiments. Those of ordinary skill in the art to which the present invention pertains will appreciate that the present invention may be embodied in modified forms without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative point of view, not from a restrictive point of view. The scope of the present invention is defined by the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention

[Accession Number]

[0074] Depository Authority: Korean Culture Center of Microorganisms (KCCM)

[0075] Accession Number: KCCM13339P

[0076] Deposit Date: Mar. 29, 2023

SEQUENCE LISTING

Sequence total quantity: 9

SEQ ID NO: 1 moltype = DNA length = 2097
 FEATURE Location/Qualifiers
 source 1..2097
 mol_type = other DNA
 organism = synthetic construct

SEQUENCE: 1

atggcatccg	atattattag	aactgactta	gtcgcttttag	acgcagactt	aggcacctca	60
gttgaatcag	taattaccca	actagccacg	ttagttcacg	acgctggctg	cgccagcaac	120
gtggaagaat	tagcgcgtcc	cgcaattgag	cgtgaggccc	aagctggcac	cggagtgccct	180
ggcaaggtag	caatcccgcga	ctgccgttcc	gcagcagtga	gcgagccaac	cttggttttt	240
gcgcgacttt	ctcaagcggg	agatttcgca	ggtcctgatg	gcgatgccga	gttggtattt	300
ctgatcgctg	ccccggaagg	cggcggcaaa	gcgcacctga	agattctttc	caagcttgcg	360
cgtgcactgg	tgcgccagga	tttctcgac	gcgcttcgta	ctgcaagctc	agaagaagaa	420
atcgctcgctt	tagttagcga	tgtcgtcagc	gccgaaaaga	aagcaccgac	cagtgcgaagc	480
tcagggtccaa	cagagggggc	gtcgacgaac	gaggcatcga	caagcgaagc	atcgacaagc	540
actgcgaaaag	ctttgaacat	tgttgctgtc	accgcctgcc	ccacaggtat	tgctcacacc	600
tacatggctg	ccgacgcctc	gagccaaacc	gcagaaaagc	gcgatgacat	caaactcacg	660
gtagaaaccc	aaggctcgct	caataacacc	ccggttgcac	aatcggtcat	cgacgccgct	720
gatgccgtaa	tcttcgttac	cgatgtggga	gtacgcgacc	gcgaacgctt	cgctggaaaa	780
cccgctcatcg	aatccggtgt	aaaacgcgct	atcaacgaac	ctgatgtcat	gctgaacgaa	840
gtcgcttgctg	cggcgcaaaa	ccctaactca	cacaaggtta	gcggtagcgc	agcaatctct	900
tctggcacgg	aggataccgc	tagccagctc	agctggggca	agcgcaccca	gcaggccgta	960
atgaccgggtg	tgtcctacat	ggtgcccttc	gtagccgctg	gcggtttgct	actagcactg	1020
ggctttttat	tcggaggcgc	cgatatggcc	aatggctggc	aggccatctc	taccaggtat	1080
tcactgacca	acctgccggg	gcacgaggtc	gacgtcgacg	gtgagctcct	cagctttgaa	1140
cgctctggac	tcctgctata	tatcggcgcg	gtgctctttg	ccaccggcca	agcctccatg	1200
ggctttatcg	tctcagccct	atctggctat	attgettacg	ctttggctgg	gcgccctggt	1260
atcgcgccgg	gctttgctgg	cggcgcaatc	gctgtcaccg	tcggcgccgg	cttcacgctg	1320
ggtctggtca	caggtctact	cgcgggtctt	atcgcaatgt	ggatcggtct	atggaaggtg	1380
ccgcgctgga	tgaattcttt	aatgccagtg	atgctcattc	cgctggtgac	cactttggtg	1440
gttggtctcg	caatgtactt	cgtgctgggc	gcaccgctgg	aagcgttgat	gactggcctg	1500
caaaaacatgc	ttggtggcat	gtctggttct	tctgccgtgg	tgctgggcat	cgtgctgggc	1560
ctaattgatgt	gttctgacct	gggtggccca	attaataagg	ctgcctacct	cttcggtacc	1620
gcagggtctt	ccaccggtga	tcagcatcc	ctggaaatca	tggcagcgat	catggcctcc	1680
ggtatggttc	caccaattgc	ttgtctgatt	gcaaccatcg	tgcgcaagaa	cctctttacc	1740
cctgcggagc	aagaaaacgg	caagtcttcc	tggtgatagg	gtctggcctt	cgtctccgag	1800
ggcgcgattc	cattcgctgc	tgcgcaccca	ttccgcgtca	ttccagcgat	gatggctggt	1860
ggcgccacta	ccggtgcgct	catcatggca	ctcggtgtgg	gctcacgtgc	ttccgacggt	1920
ggtatcttcg	tgctctttgc	tatcgaaacct	atctggggct	acatcgctgc	catcctgggtc	1980
ggtaactttg	ttgcggctgt	cgcgcgtcat	gctttgaagc	aattttggcc	aaataagacc	2040
atccaggaag	cagcagcaaa	agatgcacga	gaaaaatcag	ccctcgcagc	tgcttaa	2097

SEQ ID NO: 2 moltype = AA length = 698
 FEATURE Location/Qualifiers
 source 1..698
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 2

MASDIIRTDL	VALDADLGT	VESVITQLAT	LVHDAGRASN	VEELARPAIE	REAQAGTGVP	60
GKVAIPHCRS	AAVSEPTLAF	ARLSQAVDFA	GPDGDALVLF	LIAAPEGGGK	AHLKILSKLA	120
RALVRQDFLD	ALRTASSEEE	IVALVSDVVS	AEKKAPTSAS	SGPTEGASTN	EASTSEASTS	180
TAKALNIVAV	TACPTGLIAHT	YMAADALSQT	AEKRDDIKLT	VETQSSNNT	PVAQSVIDAA	240
DAVIFATDVG	VRDRERFAGK	PVIESGVKRA	INEPDVMLNE	VVAAAQNPNS	HKVSGSAAIS	300
SGTETASQL	SWGKRIQAV	MTGVSYMVPF	VAAGLLLLAL	GFLFGGADMA	NGWQAISTQY	360
SLTNLPGHEV	DVDGELLSFE	RSGLLLYIGA	VLFPATGQASM	GFIVSALSGY	IAYALAGRP	420
IAPGFAGGAI	AVTVGAGFIG	GLVTGLLAGL	IAMWIGSWKV	PRWMNSLMPV	MLIPLLTTLV	480
VGLAMYFVLG	APLEALMTGL	QNMLGGMSSG	SAVVLGIVLG	LMMCSDLGGP	INKAAYLFGT	540
AGLSTGDQAS	LEIMAAIMAS	GMVPPIALSI	ATIVRKNLFT	PAEQENGKSS	WLMGLAFVSE	600
GAIPIFAAADP	FRVIPANMAG	GATTGALIMA	LGVGSRAPHG	GIFVLFAIEP	IWGYIVAILV	660
GTLVAAVAVI	ALKQFWPNKT	IQEAAAKDAR	EKSALAAA			698

SEQ ID NO: 3 moltype = DNA length = 2097
 FEATURE Location/Qualifiers
 source 1..2097
 mol_type = genomic DNA
 organism = Corynebacterium stationis

SEQUENCE: 3

atggcatccg	atattattag	aactgactta	gtcgcttttag	acgcagactt	aggcacctca	60
gttgaatcag	taattaccca	actagccacg	ttagttcacg	acgctggctg	cgccagcaac	120
gtggaagaat	tagcgcgtcc	cgcaattgag	cgtgaggccc	aagctggcac	cggagtgccct	180
ggcaaggtag	caatcccgcga	ctgccgttcc	gcagcagtga	gcgagccaac	cttggttttt	240
gcgcgacttt	ctcaagcggg	agatttcgca	ggtcctgatg	gcgatgccga	gttggtattt	300
ctgatcgctg	ccccggaagg	cggcggcaaa	gcgcacctga	agattctttc	caagcttgcg	360
cgtgcactgg	tgcgccagga	tttctcgac	gcgcttcgta	ctgcaagctc	agaagaagaa	420

-continued

```

atcgctcgctt tagttagcga tgtcgtcagc gccgaaaaga aagcaccgac cagtgcgaagc 480
tcaggtccaa cagagggggc gtcgacgaac gaggcacgca caagcgaagc atcgacaagc 540
actgcgaaag ctttgaacat tgttgctgtc accgcctgcc ccacaggtag tgctcacacc 600
tacatggctg cgcagcgccct gagccaaacc gcagaaaagc gcgatgacat caaactcacg 660
gtagaaaccc aaggctcgct caataacacc ccggttgcac aatcggtcat cgacgcgcgt 720
gatgccgtaa tcttcgctac cgaatgtgga gtacgcgacc gcgaacgctt cgctggaaaa 780
cccgctcatg aatccggtgt aaaacgcgct atcaacgaac ctgatgtcat gctgaacgaa 840
gccgttgctg cggcgcaaaa ccttaactca cacaaggtta gcggtagcgc agcaatctct 900
tctggcacgg aggataccgc tagccagctc agctggggca agcgcaccca gcaggccgta 960
atgaccgggtg tgtcctacat ggtgcccttc gtagccgctg gcggtttgct actagcactg 1020
ggctttttat tcggaggcgc cgatatggcc aatggctggc aggccatctc taccaggtat 1080
tcactgacca acctgccggg gcacgaggtc gacgtcgacg gtgagctcct cagctttgaa 1140
cgctctggac tctctgtata tatcgccgcg gtgctctttg ccacccgcca agcctccatg 1200
ggctttatcg tctcagccct atctggctat attgcttacg ctttggctgg gcgccctggt 1260
atcgcccgcg gctttgtctg cggcgcaatc gctgtcaccg tcggcgccgg cttcatcggt 1320
ggctctgtga caggtctact cgcgggtctt atcgcaatgt ggatcggtc atggaagggtg 1380
ccgcgctgga tgaattcttt aatgccagtg atgctcattc cgctgttgac caatttgggtg 1440
gttggtctcg caatgtactt cgtgctgggc gcaccgctgg aagcgttgat gactggcctg 1500
caaaacatgc ttggtggcat gtcgtgttct tctgcccgtg tgcgtgggcat cgtgctgggc 1560
ctaattgatg gttctgacct ggggtggcca attaataagg ctgctacct cttcggtacc 1620
gcagggtctt ccacgcgtga tcaagcatcc ctggaatca tggcagcgat catggcctcc 1680
ggatgtggtc caccgaattg ttgtcgatt gcaaccatcg tgcgcaagaa cctctttacc 1740
cctgcggagc aagaaaacgg caagtcttcc tggctgatgg gctcggctct cgtctccgag 1800
ggcgcgatcc cattcgctgc tgcgcaccca ttcccgctca ttccagcgat gatggctggt 1860
ggcgccacta ccggtgcgct catcatggca ctcggtgtgg gctcacgtgc tccgcacggt 1920
ggatatcttc tgetctttgc tategaacct atctggggct acatcgttgc catcctgggtc 1980
ggtaactttg ttgcggctgt cgcgcgcatc gctttgaagc aattttggcc aaataagacc 2040
atccaggaag cagcagcaaa agatgcacga gaaaaatcag ccctcgagc tgcttaa 2097

```

```

SEQ ID NO: 4      moltype = AA length = 698
FEATURE          Location/Qualifiers
source           1..698
                 mol_type = protein
                 organism = Corynebacterium stationis

```

```

SEQUENCE: 4
MASDIIRTDL VALDADLGS VESVITQLAT LVHDAGRASN VEELARPAIE REAQAGTGVP 60
GKVAIPHCRS AAVSEPTLAF ARLSQAVDFA GPDGDAELVF LIAAPEGGGK AHLKILSKLA 120
RALVRQDFLD ALRTASSEEE IVALVSDVVS AEKKAPTSAS SGPTEGASTN EASTSEASTS 180
TAKALNIVAV TACPTGIAHT YMAADALSQT AEKRDDIKLT VETQSSNNT PVAQSVIDA 240
DAVIFATDVG VRDRERFAGK PVIESGVKRA INEPDVMLNE AVAAAQNPNS HKVSGSAAIS 300
SGTETASQL SWGKRIQAV MTGVSVMVPF VAAGLLLLAL GFLFGGADMA NGWQAISTQY 360
SLTNLPHEV DVGELLSFE RSGLLLYIGA VLFATGQASM GFIVSALSGY IAYALAGRP 420
IAPGFAGGAI AVTVGAGFIG GLVTGLLAGL IAMWIGSWKV PRWMNSLMPV MLIPLLTLV 480
VGLAMYFVLG APLEALMTGL QNMLGGMSG SSVVLGIVLG LMMCSDLGGP INKAAYLFGT 540
AGLSTGDQAS LEIMAAIMAS GMVPPIALSI ATIVRKNLFT PAEQENGKSS WLMGLAFVSE 600
GAIPFAAADP FRVIPAMMAG GATTGALIMA LGVGSRAHPG GIFVLFAIEP IWGYIVAILV 660
GTLVAAVAVI ALKQFWPNTK IQEAAAKDAR EKSALAAA 698

```

```

SEQ ID NO: 5      moltype = DNA length = 5719
FEATURE          Location/Qualifiers
source           1..5719
                 mol_type = other DNA
                 organism = synthetic construct

```

```

SEQUENCE: 5
tgccgcaagc actcaggcg ccaaggctgc taaaggaagc ggaacacgta gaaagccagt 60
ccgcagaaac ggtgctgacc ccggatgaat gtcagctact gggctatctg gacaagggaa 120
aacgcaagcg caaagagaaa gcaggtagct tgcagtgggc ttacatggcg atagctagac 180
tgggcggttt tatggacagc aagcgaaccg gaattgccag ctggggcgcc ctctggttaag 240
gttgggaagc cctgcaaaag aaactggatg gctttcttgc cgccaaggat ctgatggcgc 300
aggggatcaa gatctgatca agagacagga taggagatcg ttccgatgat tgaacaagat 360
ggattgcacg caggtttctc gcccgcttgg gtggagagcg tattcggtca tgactgggca 420
caacagacaa tcggctgctc tgatgccgcc gtgttccggc tgtcagcgca gggggcggcg 480
gttctttttg tcaagaccga cctgtccggt gccctgaatg aactccaaga cgaggcagcg 540
cggtatcgt ggctggccac gacgggcggt ccttgccgag ctgtgctcga cgttgctcact 600
gaagcgggaa gggactggct gctattgggc gaagtgcggg ggcaggatct cctgctatct 660
caccttgctc ctgcccagaa agtatccatc atggctgatg caatgcggcg gctgcatacg 720
cttgatccgg ctacctgcc attcgaccac caagcgaaac atcgcatcga gcgagcacgt 780
actcggatgg aagccggtct tctcgatcag gatgatctgg acgaagaca tcaggggctc 840
gcgccagccg aactgttcgc caggtcgaag gcgcggatgc ccgacggcga ggatctcgtc 900
gtgacccatg gcgatgcctg cttgccgaat atcatgggtg aaaaatggcg cttttctgga 960
ttcatcgact gtggccggct ggggtgtggc gaccgctatc aggacatagc gttggctacc 1020
cgtgatattg ctgaagagct tggcggcgaa tgggctgacc gcttctcgtg gctttacggt 1080
atcgccgctc ccgattcgca gcgcacgcc ttctatcgcc ttcttgacga gttctctga 1140
gcgggactct ggggttcgct agaggatcga tcctttttaa cccatcacat atacctgccg 1200
ttcaactatta tttagtgaaa tgagatatta tgatatcttc tgaattgtga ttaaaaggc 1260
aactttatgc ccatgcaaca gaaactataa aaaatacaga gaatgaaaag aaacagatag 1320

```

-continued

atTTTTtagt	tctttaggcc	cgtagtctgc	aaatcctttt	atgattttct	atcaaacaaa	1380
agaggaaaat	agaccagttg	caatccaaac	gagagtctaa	tagaatgagg	tcgaaaagta	1440
aatcgcgcgg	gtttgttact	gataaagcag	gcaagaccta	aaatgtgtaa	aggggcaagt	1500
gtatactttg	gcgtcacccc	ttacatat	taggtctttt	tttatgtg	gtactaact	1560
tgccatcttc	aaacaggagg	gctggaagaa	gcagaccgct	aacacagtac	ataaaaaagg	1620
agacatgaac	gatgaacatc	aaaaagtttg	caaaacaagc	aacagtatta	acctttacta	1680
ccgactgct	ggcaggaggc	gcaactcaag	cgtttgcgaa	agaaacgaac	caaaagccat	1740
ataaggaaaac	atacggcatt	tcccatatta	cacgccaatga	tatgctgcaa	atccctgaac	1800
agcaaaaaaa	tgaaaaatat	caagtttctg	aatttgatto	gtccacaatt	aaaaatatct	1860
cttctgcaaa	aggcctggac	gtttgggaca	gctggccatt	acaaaacgct	gacggcactg	1920
tcgcaaaacta	tcacggctct	cacatcgctc	ttgcattagc	cggagatcct	aaaaatgctg	1980
atgcacacatc	gatttacatg	ttctatcaaa	aagtcggcga	aacttctatt	gacagctgga	2040
aaaacgctgg	ccgcgtcttt	aaagacagcg	acaaattcga	tgcaaatgat	tctatcctaa	2100
aagaccaaac	acaagaatgg	tcagggttcag	ccacatttac	atctgacgga	aaaatccgtt	2160
tattctacac	tgattttctcc	ggtaaacatt	acggcaaaac	aacactgaca	actgcacaag	2220
ttaacgtatc	agcatcagac	agctctttga	acatcaacgg	tgtagaggat	tataaatcaa	2280
tctttgacgg	tgacggaaaa	acgtatcaaa	atgtacagca	gttcatcgat	gaaggcaact	2340
acagctcagg	cgacaacccat	acgctgagag	atccctcacta	cgtagaagat	aaaggccaca	2400
aatacttagt	atttgaagca	aacactggaa	ctgaagatgg	ctaccaaggg	gaagaatctt	2460
tatttaacaa	agcatactat	ggcaaaagca	catcattctt	ccgtcaagaa	agtcaaaaac	2520
tctctcaaa	cgataaaaaa	cgcacggctg	agttagcaaa	cggcgctctc	ggtagattg	2580
agctaaacga	tgattacaca	ctgaaaaaag	tgatgaacc	gctgattgca	tctaacacag	2640
taacagatga	aattgaacgc	gcgaacgtct	ttaaaatgaa	cggcaaatgg	tacctgttca	2700
ctgactcccg	cggatcaaaa	atgacgattg	acggcattac	gtctaacgat	atttacatgc	2760
ttggttatgt	ttctaattct	ttaaactggc	catacaagcc	gctgaacaaa	actggccttg	2820
tgtaaaaaat	ggatcttgat	cctaacgatg	taacctttac	ttactcacac	ttcgtgtgac	2880
ctcaagcgaa	aggaacaacat	gtcgtgatta	caagctatat	gacaacacaga	ggattctacg	2940
cagacaaaac	atcaacgttt	gcgcgcgact	tcttctgtaa	catcaaaggg	aagaaaaacat	3000
ctgttgtcaa	agacagacatc	cttgaacaag	gacaattaac	agttaacaaa	taaaaacgca	3060
aaagaaaatg	ccgatgggta	ccgagcgaaa	tgaccgacca	agcgacgccc	aaactgccat	3120
cacgagattt	cgattccaac	gccgccttct	atgaaagggt	gggtctcgga	atcgttttcc	3180
gggacgcctt	cgcggacgtg	ctcatagtc	acgacgcctg	tgattttgta	gccctggcgg	3240
acggcccgca	ggtagggcca	caggctcatg	ccggccgcgg	ccgccttttc	ctcaatcgct	3300
cttcgttcgt	cttgaaggca	gtacaccttg	ataggtgggc	tgcccttctc	ggttggttg	3360
gtttcatcag	ccatccgctt	gccctcatct	gttacgcggg	cggtagccgg	ccagcctgc	3420
agagcaggat	tcccgctgag	caccgccagg	tgcaataaag	ggacagtga	gaaggaaacac	3480
ccgctcgcgg	gtgggcctac	ttcaactatc	ctgcgccgct	gacgcgcttg	gataacacaa	3540
ggaaagtcta	cacgaacctt	ttggcaaaat	cctgtatata	gtgcgaaaaa	ggatggatat	3600
accgaaaaaa	tcgctataat	gaccccgaa	cagggttatg	cagcgaaaaa	gcgctgcttc	3660
cctgctgttt	tgtggaatat	ctaccgactg	gaaacaggca	aatgcaggaa	attactgaac	3720
tgaggggaca	ggcgagagac	gatgccaaa	agctcctgaa	aatctcgata	actcaaaaaa	3780
tacgcccgtg	agtgatctta	tttcattatg	gtgaaagtgt	gaacctctta	cgtgccgatc	3840
aaactctcat	tttcgcgaaa	agttggccca	gggcttcccg	gtatcaacag	ggacaccagg	3900
atattattat	tctgcgaagt	gatcttccgt	cacagggtat	tattcggcgc	aaagtgcgtc	3960
gggtgatgct	gccaaactac	tgatttagtg	tatgatgggt	tttttgaggt	gctccagttg	4020
cttcgttttc	tatcgactcc	tgaaaaatctc	gataactcaa	aaaatacgcc	cggtagtgtat	4080
cttatttcat	tatggtgaaa	gttggaacct	cttacgtgcc	gatcaacgtc	tcatttttcg	4140
caaaagtgtg	cccagggtct	cccggtatca	acagggacac	caggatttat	ttattctgcg	4200
aagtgatctt	ccgtcacagg	tatttatctg	gcgcaaaagt	cgtcgggtga	tgctgccaac	4260
ttactgattt	agtgtatgat	gggtgttttg	aggtgctcca	gtggcttctg	tttctatcag	4320
ggctggatga	tccctcacgg	cggggatctc	atgctggagt	tcttcgcccc	ccccaaaagg	4380
atctaggtag	agatcccttt	tgataatctc	atgacccaaa	tcccttaacg	tgagttttctg	4440
ttccactgag	cgtcagaccc	cgtagaaaa	atcaaaaggat	cttcttgaga	tccttttttt	4500
ctgcgcgtaa	tctgctgctt	gcaaaacaaa	aaaccaccgc	taccagcggg	ggttgttttg	4560
ccggatcaag	agctaccaac	tctttttccg	aaggtaactg	gcttcagcag	agcgcagata	4620
ccaaatactg	ttcttctagt	gtagccgtag	ttaggccacc	acttcaagaa	ctctgtagca	4680
ccgcctacat	acctcgctct	gctaactcgt	ttaccagtg	ctgctgccag	tgccgataag	4740
tcgtgtctta	ccgggttgga	ctcaagacga	tagttaccgg	ataaggcgca	gcggtcgggc	4800
tgaacggggg	gttcgtgcac	acagcccgac	ttggagcgaa	cgacctacac	cgaactgaga	4860
tacctacagc	gtgagctatg	agaaagcgcc	acgcttcccg	aaggggagaaa	ggcggacagg	4920
tatccggtaa	cgcgccagggt	cggaacaggga	gagcgcaagca	gggagcttcc	agggggaaac	4980
gcctgggtatc	tttatagttc	tgtcgggttt	cgccacctct	gacttgagcg	tcgatttttg	5040
tgatgctcgt	cagggggggcg	gagcctatgg	aaaaacgcca	gcaacgcggc	ctttttacgg	5100
ttcctggcct	tttgcgtggc	ttttgctcac	atgttctttc	ctgcgttatc	ccctgattct	5160
gtggataacc	gtattaccgc	cttttagtga	gctgataccg	ctgcgcgcag	ccgaacgacc	5220
gagcgcgacg	agtcagtgag	cgaaggaagcg	gaagagcgcc	caatacgcaa	accgcctctc	5280
cccgcgcttt	ggcagattca	ttaatgcagc	tggcacgaca	ggtttcccgca	ctggaagacg	5340
ggcagtgagc	gcaacgcaat	taattgtgag	tagctcactc	attaggcacc	ccaggcttta	5400
cactttatgc	ttccggctcg	tatgttgtgt	ggaattgtga	gcggataaca	atttcacaca	5460
ggaaacagct	atgacatgat	tacgccaaagc	ttgcatgcct	gcaggctcgac	tctagaggat	5520
ccccgggtac	ccagctcgaa	ttcaactggc	gtcgtttttac	aacgtcgtga	ctgggaaaaac	5580
cctggcggtta	ccccacttaa	tcgccttgca	gcacatcccc	ctttcgcacg	ctggcgtaac	5640
agcgaagagg	ccccgaccga	tcgcccttcc	caacagttgc	gcagcctgaa	tggcgaatgg	5700
cgataagcta	gcttcacgc					5719

-continued

FEATURE	Location/Qualifiers	
source	1..20	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 6		
cggcaaagcg cacctgaaga		20
SEQ ID NO: 7	moltype = DNA length = 21	
FEATURE	Location/Qualifiers	
source	1..21	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 7		
cgcgagcaac gacttcgttc a		21
SEQ ID NO: 8	moltype = DNA length = 21	
FEATURE	Location/Qualifiers	
source	1..21	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 8		
tgaacgaagt cggtgctgcg g		21
SEQ ID NO: 9	moltype = DNA length = 23	
FEATURE	Location/Qualifiers	
source	1..23	
	mol_type = other DNA	
	organism = synthetic construct	
SEQUENCE: 9		
tccatgagcc gatccacatt gcg		23

1. A PTS transporter subunit EIIC variant consisting of the amino acid sequence of SEQ ID NO: 2 in which alanine at position **281** in the amino acid sequence of SEQ ID NO: 4 is substituted with valine.

2. A polynucleotide encoding the variant of claim 1.

3. A transformant comprising the variant of claim 1.

4. The transformant of claim 3, which is a *Corynebacterium stationis*.

5. The transformant of claim 3, which has ability to produce 5'-inosinic acid.

6. A method for producing 5'-inosinic acid, comprising steps of:

culturing the transformant of claim 3 in a medium; and recovering 5'-inosinic acid from the transformant or the medium in which the transformant has been cultured.

7. A transformant comprising the polynucleotide of claim 2.

* * * * *